

**To** NZX Limited; and Name of listed issuer:

## **Ongoing Disclosure Notice**

## **Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

Date this disclosure made:	12 December 2025
Date of last disclosure:	22 May 2025
Director or senior manager giving disclosure	
Full name(s):	Brien Herbert Cree
Name of listed issuer:	Radius Residential Care Limited
Name of related body corporate (if applicable):	Kade Kings Limited
Position held in listed issuer:	Executive Chairman & Founder
	Executive Chairman & Founder
Summary of acquisition or disposal of relevant interest (excluding specified de	erivatives)
Class of affected quoted financial products:	Ordinary shares of Radius Residential Care Limited (NZX: RAD)
Nature of the affected relevant interest(s):	All of the shares of Kade Kings Limited are held by Richmond Road Trustees Limited, which holds them on bare trust for The Providence Trust. Brien Cree has a relevant interest in the shares held by Kade Kings Limited, because Brien Cree has the power to exercise control of the right to vote attached to, and (indirectly) the power to control the disposal of, the shares held by Kade Kings Limited and has power to control the appointment and removal of trustees to The Providence Trust
For that relevant interest-	
Number held in class before acquisition or disposal:	95,312,500
Number held in class after acquisition or disposal:	94,821,579
Current registered holder(s):	Kade Kings Limited
Registered holder(s) once transfers are registered:	Unknown
Summary of acquisition or disposal of specified derivatives relevant interest (if	f applicable)
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
•	

Radius Residential Care Limited

Maturity date of the derivative (if any):	N/A
Expiry date of the derivative(if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative,-	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Six
Details of transactions requiring disclosure-	(a) 5 December 2025
	<ul><li>(b) 8 December 2025</li><li>(c) 9 December 2025</li><li>(d) 10 December 2025</li><li>(e) 11 December 2025</li></ul>
Date of transaction:	(f) 12 December 2025
	To ensure ongoing compliance with Clause 5 of the Takeovers Code (Class Exemptions) Notice (No 2) 2001, 490,921 ordinary shares of Radius Residential Care Limited have been disposed of, on-market, to
Nature of transaction:	unknown buyers
Name of any other party or parties to the transaction (if known):  The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	Unknown \$187,570.17 comprised of: (a) \$12,013.35 (b) \$5,591.76 (c) \$2,697.25 (d) \$31,137.55 (e) \$40,614.26 (f) \$95,516.00 (a) 31,015 (b) 13,975 (c) 6,777 (d) 79,236 (e) 107,297 (f) 252,621
Number of financial products to which the transaction related:  If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	Total (490,921)
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
	<del>-</del>

For that relevant interest,-	
Number held in class:	N/A
Current registered holder(s):	N/A
For a derivative relevant interest,-	
Type of derivative:	N/A
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative relevant interest,-	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Kohrlah
Date of signature:	12 December 2025
Name and title of authorised person:	Rohan Cook, Company Secretary